Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	Pathological Complete Response (pCR) rate	At the time of surgery, approximately 9-15 weeks after enrollment	The percentage of subjects with no residual viable tumor cells in the resected primary tumor bed and lymph nodes after lung cancer resection.
Secondary	Major Pathological Response (MPR) rate	At the time of surgery, approximately 9-15 weeks after enrollment	The percentage of subjects with ≤10% residual viable tumor cells in the resected primary tumor bed and lymph nodes after lung cancer resection.
Secondary	Objective Response Rate (ORR)	From enrollment to pre-surgery assessment, approximately 9-15 weeks	The proportion of subjects achieving complete response (CR) or partial response (PR) on imaging according to RECIST v1.1 criteria prior to surgery.
Secondary	R0 Resection Rate	At the time of surgery	The percentage of subjects undergoing lung cancer resection who achieve complete resection with negative margins.
Secondary	Event-Free Survival (EFS)	From enrollment to up to 2 years post-surgery	Defined as the time from first study drug administration to the occurrence of disease progression precluding surgery, local or distant recurrence, or death from any cause.
Secondary	Overall Survival (OS)	From enrollment to up to 2 years post-surgery or death	Defined as the time from first study drug administration to death from any cause.
Secondary	Safety and Tolerability	From first dose to 90 days after last dose	Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI-CTCAE v5.0; rates of dose interruptions, modifications, and discontinuations due to AEs.
Secondary	Rate of Delayed or Cancelled Surgery	From completion of neoadjuvant therapy to scheduled surgery date, approximately 6 weeks	The percentage of subjects whose planned surgery is delayed beyond the protocol-specified window or cancelled.
Secondary	Surgery Duration	At the time of surgery	The total time from surgical incision to closure, measured in minutes.
Secondary	Hospitalization Duration	From surgery date to hospital discharge, approximately 1-4 weeks	The total number of days from surgery to hospital discharge.
Secondary	Surgical Method	At the time of surgery	The type of surgical procedure performed (e.g., lobectomy, pneumonectomy, sleeve resection, etc.) and surgical approach (e.g., open thoracotomy, video-assisted thoracoscopic surgery \[VATS\]).
Secondary	Incidence of Surgery-Related Adverse Events	From surgery to 90 days post-surgery	The incidence and severity of surgery-related adverse events, including intraoperative complications (e.g., pneumonia, respiratory distress syndrome, packed red blood cell transfusion, bronchopleural fistula, air leak), readmission to intensive care unit, atrial fibrillation, and other supraventricular tachycardia (SVT).

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07538193/registered

API reference For AI assistants